STENT GRAFT WITH RELEASABLE THERAPEUTIC AGENT AND SOLUABLE COATING

• US 20080167724A1
• Filed: 12/17/2007
• Published: 07/10/2008
• Est. Priority Date: 12/18/2006
• Status: Active Grant

• Current Assignee: Cook Medical Incorporated (Cook Group Incorporated)
• Original Assignee: MED Institute, Inc. (Cook Group Incorporated)
• Inventors: Reyes, Priscilla, Ruane, Patrick H., Roeder, Blayne A., Vibbert, Amy M.
• Granted Patent: US 9,474,833 B2
• Time in Patent Office: Days
• US Class Current: 623/23.7
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 75/04 Polyurethanes

Abstract

Medical devices for implantation within a body vessel comprising a graft material and a releasable therapeutic agent are provided. The graft material preferably comprises a biocompatible polyurethane and a therapeutic agent. Preferably, the medical device is a stent graft formed by attaching a polyurethane graft material comprising an elutable taxane therapeutic agent to a radially expandable frame.

Claims

1. A method of treating a biliary tumor comprising the steps of

a. intralumenally inserting a radially expandable coated stent graft in a radially compressed configuration into a body vessel, the coated stent graft having an abluminal surface with a surface area and a luminal surface defining a drainage lumen, the coated stent graft having a graft material attached to a radially expandable support frame, and a coating comprising a poly(alkyl glycol) polymer on the abluminal surface of the graft material;

the graft material containing a taxane therapeutic agent and a polyurethane polymer and forming at least a portion of both the luminal surface and the abluminal surface, the graft material formed from a polymer including polydimethylsiloxane and a polyurethane and further including about 5-100 micrograms of the taxane therapeutic agent per mm² of the surface area of the abluminal surface with a weight ratio of the taxane therapeutic agent to the poly(alkylene glycol) of between about 0.10 and 3.50;

b. translating the stent graft within the body vessel to position the stent graft within a biliary duct proximate the biliary tumor; and

c. radially expanding the stent graft within the biliary duct so as to place the stent graft in contact with a portion of a wall of the biliary duct in a manner effective to deliver the taxane therapeutic agent to the wall of the biliary duct.

2. The method of claim 1, further comprising the step of retaining at least 20% wt of the taxane therapeutic agent in the graft after 90 hours of contacting the abluminal surface with the wall of the biliary duct.

3. The method of claim 1, where the poly(alkyl glycol) is poly(ethylene glycol).

4. The method of claim 1, where the graft material comprises a total of about 5-25 milligrams of the taxane therapeutic agent.

5. The method of claim 3, where the graft material comprises a total of 10-15 milligrams paclitaxel and about 3-60 micrograms paclitaxel per mm² of the abluminal surface area.

6. The method of claim 5, where the graft material comprises a total of 5-100 milligrams of the poly(ethylene glycol) and about 5-100 micrograms poly(ethylene glycol) per mm² of the abluminal surface area).

7. The method of claim 6, where the poly(ethylene glycol) has a weight average molecular weight in the range from 100 to about 10,000.

8. The method of claim 7, where increasing the total amount of the taxane therapeutic agent in the graft material increases the time required to elute 80% of the taxane therapeutic agent by weight from the graft material in vitro in a 0.5% aqueous SDS solution at 25°

C.

9. The method of claim 8, where the graft material comprises a modified solid polymer blend formed of a base polymer comprising the polyurethane and a solid thermoplastic segmented block copolymer additive blended with the base polymer, the additive comprising a first essentially linear segmented copolymer chain and a second essentially linear polymer chain chemically bonded to said first segmented copolymer chain, said second polymer chain being selected from a polar homopolymer or a second segmented copolymer;

said additive characterized by a γ

_c less than said base polymer and said first segmented copolymer chain characterized by the presence of at least one polar hard segment having a glass transition temperature or crystalline melting temperature above 37°

C., and a nonpolar soft block having a glass transition temperature or crystalline melting temperature below 37°

C.;

said second segmented copolymer or polar homopolymer characterized by the presence of at least one second polar hard segment having a glass transition temperature or crystalline melting temperature above 37°

C., and said second segmented copolymer further characterized by the presence of a polar soft block having a glass transition temperature or crystalline melting temperature below 37°

C., said polar hard segments independently selected from the group consisting of a polyurethane and a polyurethaneurea.

10. A coated tubular stent graft having an abluminal surface with a surface area and a luminal surface defining a drainage lumen, the coated stent graft comprising:

a graft material attached to a radially expandable support frame to form at least a portion of both the luminal surface and the abluminal surface of the coated tubular stent graft and a coating including a glycol polymer on the portion of the graft material forming the abluminal surface, the graft material containing about 5-100 micrograms of a taxane therapeutic agent per mm² of the surface area of the abluminal surface and a polyurethane polymer comprising a polymer including polydimethylsiloxane and a polyurethane, the stent graft having a weight ratio of the taxane therapeutic agent to the glycol of between about 0.10 and 3.50.

11. The stent graft of claim 10, where increasing the total amount of the taxane therapeutic agent in the graft material increases the time required to elute 80% of the taxane therapeutic agent by weight from the graft material in vitro in a 0.5% aqueous SDS solution at 25°

C.

12. The stent graft of claim 11, where increasing the temperature of the graft material from 25°

C. to 37°

C. increases the time required to elute 80% of the taxane therapeutic agent by weight from the graft material in vitro in a 0.5% aqueous SDS solution.

13. The stent graft of claim 10, where the glycol polymer is poly(ethylene glycol) with a weight average molecular weight in the range from 100 to about 10,000.

14. The method of claim 10, where the graft material comprises a total of about 5-25 milligrams of the taxane therapeutic agent.

15. The stent graft of claim 14, where the graft material comprises a total of 10-15 milligrams paclitaxel and about 3-60 micrograms paclitaxel per mm² of the abluminal surface area.

16. The stent graft of claim 15, where the graft material comprises a total of 5-100 milligrams of the poly(ethylene glycol) and about 5-100 micrograms poly(ethylene glycol) per mm² of the abluminal surface area).

17. The stent graft of claim 16, where the weight ratio of the total paclitaxel to the total poly(ethylene glycol) is about 0.1 to 1.50.

18. A method of manufacturing a stent graft, the method comprising the steps of:

a. forming a first solution comprising a taxane therapeutic agent, a polymer and a solvent, the concentration of the taxane therapeutic agent being less than about 400 mM in the first solution and the polymer including polydimethylsiloxane and at least one polymer selected from the group consisting of;

polyurethane and polyureaurethane;

b. contacting the first solution with a radially expandable support frame and drying at least a portion of the first solution contacting the support frame to form a graft material attached to the support frame to form an abluminal surface, the graft material containing about 5-100 micrograms of a taxane therapeutic agent per mm² of a surface area of the abluminal surface;

c. applying a poly(alkyl glycol) polymer to the graft material to form a coating consisting essentially of the poly(alkylene glycol) on at least a portion of the graft material to form a coated stent graft having a weight ratio of the taxane therapeutic agent to the poly(alkyl glycol) of between about 0.10 and 3.50.

19. The method of claim 18, where the poly(alkyl glycol) is poly(ethylene glycol) having an average molecular weight of about 1,000 and where the graft material comprises a modified solid polymer blend formed of a base polymer comprising the polyurethane and a solid thermoplastic segmented block copolymer additive blended with the base polymer, the additive comprising a first essentially linear segmented copolymer chain and a second essentially linear polymer chain chemically bonded to said first segmented copolymer chain, said second polymer chain being selected from a polar homopolymer or a second segmented copolymer;

said additive characterized by a γ

_c less than said base polymer and said first segmented copolymer chain characterized by the presence of at least one polar hard segment having a glass transition temperature or crystalline melting temperature above 37°

C., and a nonpolar soft block having a glass transition temperature or crystalline melting temperature below 37°

C.;

said second segmented copolymer or polar homopolymer characterized by the presence of at least one second polar hard segment having a glass transition temperature or crystalline melting temperature above 37°

C., and said second segmented copolymer further characterized by the presence of a polar soft block having a glass transition temperature or crystalline melting temperature below 37°

C., said polar hard segments independently selected from the group consisting of a polyurethane and a polyurethaneurea.

20. The method of claim 19, where the graft material comprises a total of 10-15 milligrams paclitaxel and about 3-60 micrograms paclitaxel per mm² of the abluminal surface area;

and where the coating consists of about 5 to 15 milligrams of poly(ethylene glycol).